The DOI matches its Crossref record; the references it cites are not checked yet.
Longitudinal structural and metabolic changes in frontotemporal dementia
Open accessAbstract
Objective To compare the sensitivity of structural MRI and 18F-fludeoxyglucose PET (18FDG-PET) to detect longitudinal changes in frontotemporal dementia (FTD). Methods Thirty patients with behavioral variant FTD (bvFTD), 7 with nonfluent/agrammatic variant primary progressive aphasia (nfvPPA), 16 with semantic variant primary progressive aphasia (svPPA), and 43 cognitively normal controls underwent 2–4 MRI and 18FDG-PET scans (total scans/visit = 270) as part of the Frontotemporal Lobar Degeneration Neuroimaging Initiative study. Linear mixed-effects models were carried out voxel-wise and in regions of interest to identify areas showing decreased volume or metabolism over time in patients as compared to controls. Results At baseline, patients with bvFTD showed bilateral temporal, dorsolateral, and medial prefrontal atrophy/hypometabolism that extended with time into adjacent structures and parietal lobe. In nfvPPA, baseline atrophy/hypometabolism in supplementary motor cortex extended with time into left greater than right precentral, dorsolateral, and dorsomedial prefrontal cortex. In svPPA, baseline atrophy/hypometabolism encompassed the anterior temporal and medial prefrontal cortex and longitudinal changes were found in temporal, orbitofrontal, and lateral parietal cortex. Across syndromes, there was substantial overlap in the brain regions showing volume and metabolism loss. Even though the pattern of metabolic decline was more extensive, metabolic changes were also more variable and sample size estimates were similar or higher for 18FDG-PET compared to MRI. Conclusion Our findings demonstrated the sensitivity of 18FDG-PET and structural MRI for tracking disease progression in FTD. Both modalities showed highly overlapping patterns of longitudinal change and comparable sample size estimates to detect longitudinal changes in future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the clinical and research utility of FDG-PET has been shown, 63 the findings are not 100% sensitive or specific for underlying frontotemporal lobar degeneration.69”
From Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredIn the citing paper
“In particular, the clinical diagnosis of each frontotemporal dementia (FTD) variant requires high levels of expertise and multidisciplinary teams to distinguish among subtle phenotypes with similar underlying physiopathological processes (Bejanin et al., 2020; Staffaroni et al., 2019; Zetterberg et al., 2019).”
From Multiclass characterization of frontotemporal dementia variants via multimodal brain network computational inference (2023) · cites this paper as Bejanin et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 46 · Cited by 70
Metadata
- Authors
- Bejanin, A., Tammewar, G., Marx, G., Cobigo, Y., Iaccarino, L., Kornak, J., Staffaroni, A. M., Dickerson, B. C., Boeve, B. F., Knopman, D. S., Gorno-Tempini, M., Miller, B. L., Jagust, W. J., Boxer, A. L., Rosen, H. J., & Rabinovici, G. D.
- Affiliations
- Mayo Clinic (US)
- From the Memory and Aging Center, Department of Neurology (A.B., G.T., G.M., Y.C., L.I., J.K., A.M.S., M.G.-T., B.L.M., A.L.B., H.J.R., G.D.R.), and Department of Radiology and Biomedical Imaging (G.D.R.), University of California San Francisco; Frontotemporal Disorders Unit (B.C.D.), Department of Neurology, Massachusetts General Hospital, Boston; and Harvard Medical School, Charleston; Department of Neurology (B.F.B., D.S.K.), Mayo Clinic, Rochester, MN; Molecular Biophysics and Integrated...
- ORCID
- Venue
- Neurology
- Published
- 2020-07-14
- Volume
- 95
- Issue
- 2
- Pages
- e140-e154
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC7455324
- OpenAlex
- W3037605026
- Cited by
- 70
- References
- 46
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 9 · 2023: 13 · 2022: 14 · 2021: 10
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Larry L. Hillblom Foundation (P01 AG019724)
- Eli Lilly and Company
- American Brain Foundation
- Biogen
- BioClinica
- FORUM Pharmaceuticals
- National Institute for Health and Care Research
- H. Lundbeck A/S
- National Institutes of Health (AG023501, AG019724, NS050915)
- Genentech
- Tau Consortium
- NIHR Cambridge Biomedical Research Centre
- National Institute on Aging (K23AG061253, AG034570, AG023501, R01AG032306, AG019724, AG052943, K24AG045333, U01AG052943, P01AG019724, R01AG034570, P30AG062422, P30AG062421, P50AG023501)
- National Institute on Deafness and Other Communication Disorders (K24DC015544)
- National Institute of Neurological Disorders and Stroke (R01NS050915)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal dementia, behavioral variant frontotemporal dementia, primary progressive aphasia, semantic variant PPA, longitudinal brain atrophy, hypometabolism, structural MRI, disease progression, sample size determination, prefrontal cortex, temporal lobe
- MeSH terms
- Aged, Atrophy, Cerebral Cortex, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Disease Progression, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Frontotemporal Dementia, Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review